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Abstract
The purpose of this thesis is to investigate the social cost motivations associated with paying for
genetic therapies at the beginning of life for monogenic diseases from various perspectives
including the social perspective and the perspective of an average member of the US
population. The findings were generated by collecting direct medical cost data (in current USD)
relevant to nine common monogenic diseases (Cystic Fibrosis, Sickle Cell Disease, Duchenne
Muscular Dystrophy, Hemophilia A, Huntington’s Disease, Polycystic Kidney Disease, Gaucher
Disease, Hereditary Angioedema, and Pompe Disease) to conduct a Monte Carlo and Net
Present Value analysis to generate robust lifetime cost distributions for each disease. One
major finding of this research is that if an individual is known to have one of theses monogenic
diseases then the direct social costs - the total cost of treatment when discounted down to a
single value at year zero of life - based on direct medical costs using a 5% discount rate for a
gene therapy which would bring about the removal of lifetime direct medical costs could be as
high as $3,568,077 (SD $599,461) for Hemophilia A or as low as $30,467 (SD $21,164) for
Huntington's syndrome. Other discount rates are also included in the models. Another major
finding is that the direct social cost at year zero of life from the social perspective using a 5%
discount rate for a gene therapy which would remove any risk of developing symptoms of, and
therefore remove the direct medical costs for, all the diseases analyzed should be $496. Direct
social cost should only increase as an individual's life continues, as explained within the thesis,
so these cost figures represent very conservative estimates. It is shown that the direct social
cost at the beginning of life for gene therapy, for individuals who are known to have monogenic
disease, can be in the millions of dollars. It is also shown that direct social cost at the beginning
of life for the removal of risk of monogenic disease in a member of the general US population
should only be a few hundred dollars. These conclusions can be interpreted to show that there
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should be a high direct social benefit for such therapies when applied to the population of
individuals who are at high risk of manifesting one of these monogenic diseases, but there
should be relatively low direct social benefit for the removal of the risks of manifesting one of
these diseases among the general US population.
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A Note on Ethics
The advancements in efficiency and precision of gene editing brought about by the
CRISPR system have allowed us to consider some previously theoretical implications of gene
editing in a new and very real light. The issues with the implications of these advancements
came to a head in 2015 when a team of Chinese scientists used the CRISPR system to remove
an abnormal gene from a non-viable human embryo. It's very important to note that this embryo
was non-viable and could never have resulted in a live birth. However, this early experiment
acted as a solid proof of concept in the scientific community and spurred vigorous discussion
and debate. This attracted the attention of the National Academy of Sciences, Engineering, and
Medicine along with the scientific agencies of several other countries including the United
Kingdom’s Royal Society and the Chinese Academy of Sciences. These agencies held the first
International Summit on Human Gene Editing in December 2015. Experts from many fields and
from all over the world were invited to join the discussion about how we might move forward with
this technology. The sentiments held at that summit were distilled into a document called
“Human Genome Editing: Science, Ethics, and Governance”.47 This document contains
comprehensive advice and policy strategies on how human genome editing might be
implemented in an ethical and fair manner. I would advise anyone with interest in the subject of
human gene editing or the policy issues and ethics thereof to read this document as it
represents the distilled sentiments of the scientists and policymakers that know the technology
best. It’s important to mention that there are two main considerations that must be taken into
account when talking about human gene editing. First, could the edits be inherited by offspring
or not? Second, is the gene editing enhancing or therapeutic? The question of inheritable
editing is important because any changes that are made can be passed down to future offspring
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of edited individuals. When gene edits are made that can not be passed down it is called
somatic editing. The question of enhancing versus therapeutic gene editing is also important
with clear extremes, however, the middle ground between the two is still undefined.
The topics of this thesis seem to sit nicely within the realm of what is considered
acceptable use of gene editing technology by the International Summit on Human Gene Editing.
These topics and methods being the alleviation of chronic disease with no alternative cure,
assuming that the methods alluded to in this work do not affect the germline and the risks of
gene therapy are limited to the individual. The treatment of disease on the level of the individual
while at the same time accepting the risks and side effects of the treatment at the level of the
individual has come to be almost the sole perspective from which we view medical treatment
(with perhaps the exception of vaccines). Where these new technologies require a deviation
from the normal perspective is when the medical decisions of an individual can begin to affect
more than just one person. If germline editing is made real then the medical decisions of
individuals can now be allowed to echo down the halls of time in the voices of our children. Most
would agree to the sentiment that gene editing should be used for the alleviation of suffering
and that if the technology is used at all for enhancement then it must be done uniformly and
fairly within the population.47 While these sentiments are well intentioned they require us to ask
questions which do not have, and may never have, clear answers. What is suffering? What is
enhancement? What is normal?
Diseases and abnormalities which cause alienation and discomfort also bring together
community and understanding. For example, dwarfism, which a member of the general
population may consider to be undesirable is actually selected for by members of the short
stature community. It will be impossible to move forward equitably until we can reach a
consensus as a society as to what the best course of action is. The concerns and implication
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regarding this technology are valid and deserve the attention of the public and the policymakers
that represent them. These concerns, while being important, are not directly addressed in this
thesis. It was never the goal of this thesis to directly address these concerns, however, it is my
hope that the findings in this work will help add to the conversation concerning these
groundbreaking advancements in gene editing.
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Introduction
Several new technologies have been developed in the last 20 years that could lead to the
possibility of genetically engineered humans within our lifetime. The most promising of these
technologies is known as CRISPR, which stands for “Clustered Regularly Interspaced Short
Palindromic Repeats”. This breakthrough technology was discovered in 2013 and allows
scientists to go into any part of an organism’s DNA and edit it in almost any way. Traditional
DNA editing methods are not as accurate and often take many tries before they are successful.
CRISPR, in combination with other technologies, could be used in the near future to modify the
DNA of humans and human embryos with more precision than ever before.1 CRISPR is also
developing into an extremely cost effective technique compared to traditional genetic
engineering methods.2 Most CRISPR product kits currently sell for under $1,000, which is close
to 5x less than traditional gene editing technologies.3 The mechanisms of CRISPR are also
relatively easy to work within the lab compared to previous gene editing methods. These
aspects in other technologies almost always lead to ubiquitous adoption and commercial
competition which drives prices down. The main question that this thesis will be trying to support
is:

How much should an individual be willing to pay to offset the direct social costs for the
prenatal removal of a genetic disease?

The focus of this thesis will be an analysis of the direct social costs - the total cost of
treatment when discounted down to a single value at year zero of life - to treat certain genetic
diseases in order to establish a conservative baseline for willingness to pay for the removal of
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those diseases’ symptoms. New genetic engineering breakthroughs like CRISPR allow us to
consider such questions. While the costs of treating many genetic diseases are relatively well
known, the potential costs of prenatal genetic engineering (PGE), or any form of genetic
engineering/therapy, are very much unknown. It is worth noting that while this thesis will use a
purely economic analysis, there are many non-economic factors that affect the practice of
human genetic engineering. While these non-economic factors, especially factors concerning
ethics and social justice, must be addressed before the technology can be allowed to move
forward they will not be addressed specifically in this thesis.
New gene editing technologies are coming faster than we might think. Some new gene
based therapies are already being developed. In the fall of 2017, a man named Brian Madeux
received a gene therapy which is aimed at functionally curing his Hunter Syndrome. Hunter
Syndrome is a genetic disease which causes limited movement and degenerative heart and
lung conditions. The gene therapy that Brian received changed the genome in some of his body
cells and, if proven effective, will allow him to live a life free of the symptoms of Hunter
Syndrome. Another notable gene therapy for a rare form of blindness was undergoing
development in the US as recently as the winter of 2018. This therapy is said to cost around
$450,000 per eye. 41
 There are also other gene therapies on the market, and most of them are
for very rare diseases. A European gene therapy called Strimvelis is aimed at curing a severe
form of immunodeficiency and costs about $665,000.42 One of the earlier gene therapies of this
kind was called Glybera, it was priced at over $1.4 million for an individual dose and was
supposed to cure a rare inherited disorder which causes severe pancreatitis.46 Glybera was
pulled from the market due to low demand. The $1.4 million price tag was meant to cover not
only the cost of developing the treatment but also to develop it in such a way that it could be
used as a toolkit to treat many different genetic diseases. These gene therapies are proving to
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be extremely expensive compared to traditional drugs. When being compared to traditional
drugs these gene therapies have one large advantage. Traditional drugs usually only treat or
manage symptoms but if a gene therapy works correctly it can completely cure a genetic
disease.
The idea of gene therapy which can be made affordable represents an admirable goal
for the future of gene editing technology. Though there is the opposing and apparently more
likely case that these therapies will become prohibitively expensive for most of the public. This
case of extreme expense seems as though it will embody the early market for gene therapy.
Given that several companies have already put gene based therapies on the market, and given
that they all cost hundreds of thousands of dollars, we must ask ourselves if the costs of these
therapies are worth the benefit.
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Literature Review

Literature Review Method
The initial search for data regarding willingness to pay for genetic therapies was
completed using Google Scholar, linked with the RIT Wallace Library database. The original
search set out to find literature on the economics for the use of genetic therapies in humans.
However, after several iterations of this search, less than three pieces of literature were found.
The reasons for this extreme lack of literature are explored in the Results and Analysis section
of this review. In order to continue exploring this topic, a new search was created. For reasons
also explored in the Results and Analysis section, the new search aimed to find current
literature on the economic costs of treatments and direct medical costs for genetic diseases in
the US. The inclusion criteria for this search only allowed for articles published in the last 10
years which included the words “Cost/Economics of Rare Disease/Orphan Drugs” in the title.
The optional terms included were "orphan drug", "rare disease", "genetic disease", “cost”,
“economics”, “treat”, "direct medical", “US”, and “United States”. A total of eight articles fully met
these criteria. Search matches were excluded if they were news articles, social or indirect cost
pieces, pieces entirely on the ethics and morals surrounding genetic disease and their
treatments or cures, and textbook entries.
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Table 1 Literature Review Matrix. Includes six articles on the most current analysis of the direct medical
costs associated with the most common genetic diseases.
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Literature Review Results

The subject of human genetic engineering is still novel in our society, Because of this,
there is very little research that directly studies the economics of human genetic engineering
and genetic therapies. Analysis of the costs of technologies and methods that have preceded
human genetic engineering, i.e. genetic testing and genetic disease treatment, are used in this
literature review to help shed light on the subject. These topics, i.e. enzyme replacement
therapy for genetic disease, have been the subject of considerable scientific and economic
study. The data and research that currently exists relative to these topics mainly consists of
economic studies of the drugs and therapies used to treat genetic diseases and evaluations of
the effectiveness of genetic tests. This data is mostly found in industry sponsored reviews and
economic reports from rare disease advocacy groups. Eight of the pieces of included literature
got their data from querying national databases. Additionally, only one multi-disease study got
its data from a survey of patients rather than a database. A majority of the single disease
studies also used patient survey data. This suggests that broad surveying of the genetically
diseased population can be difficult. However, the single disease studies show that it can be
relatively easy to gather data when one works with a specific disease. A single disease may be
easier to gather data on because oftentimes disease advocacy groups have easy access to
participants willing to take part in research. Also, research and treatment centers related to
specific genetic diseases often gather data from the entire affected population as there tend to
be only one or two of each in the US which makes them easier to query. The research pieces in
this literature review were found through NCBI and the journals of Nature, and Science.
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Overshadowing the economic research is a great deal of research into the ethical and
social implications of these and future technologies. If one was to search “genetic engineering in
humans” on Google Scholar, you would find that at least half of the first page contains material
on the ethics and morality of the subject. It is clear that most of our society views human genetic
engineering as a slippery slope and as a technology with a great deal of power. Many people in
the scientific community, including the researchers developing the technology, believe that
robust policies need to be in place before human genetic engineering technology is made
available to the public.1 The social implications of human genetic engineering are clearly
important, however, these implications are out of the scope of this review.
There is not a significant amount of research on the costs associated specifically with
genetic disease. However there is a substantial amount of information regarding rare diseases
in the US and according the the US Institute of Medicine in their review of rare diseases and
orphan drugs in the US: “experts on rare diseases generally agree that the great majority of rare
diseases—perhaps 80 percent or more—are genetic in origin”,4 the review goes on to say that
the remaining 20% of rare diseases are most likely caused by a combination of genetic and
environmental factors. Given the lack of research on genetic diseases specifically, research on
the impacts and costs of rare diseases will have to suffice. The term “rare disease” covers even
the most common monogenic disease in the US, Cystic Fibrosis,5 so the term should be suitable
for use in further analysis. The Rare Diseases Act of 2002 defines a rare disease as “any
disease or condition that affects less than 200,000 persons in the United States”.6 The National
Organization for Rare Disorders (NORD), which was instrumental in establishing the Rare
Disease Act, currently estimates 30 million Americans suffer from over 7,000 rare diseases. The
most common monogenic disease, Cystic Fibrosis, affects about 30,000 people in the US,
putting it safely within the category of a rare disease.7 With this information we can start to use
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cost data to determine the annual cost to treat the average genetic disease. Knowing what is
already spent to treat rare diseases, and by proxy, genetic diseases, it can be determined what
one might be willing to pay to cure a monogenic disease altogether.
Orphan drugs are the primary drug products used to treat rare diseases. As stated in the
2017 Orphan Drug Report published by the EvaluatePharma Group: “an orphan drug is a
pharmaceutical product aimed at rare diseases or disorders”.8 The orphan drug report also
estimates that the average cost per patient per year in 2016 was $140,450 compared to the
average $27,750 for normal (non-orphan) prescription drugs. Since orphan drug prices are
inversely correlated with the number of patients receiving the drug.9 The average calculated
cost per patient can be very high while the median costs can be significantly lower. The
EvaluatePharma report states that the median annual cost per patient is approximately $83,000.
This suggests a lognormal distribution of cost data instead of a normal distribution. A lognormal
distribution is a distribution that by definition cannot have values below zero and is hallmarked
by a long and right-skewed tail, an example of this can be seen in Figure 1. This trend of the
average cost being significantly higher than the median can be seen in most of the reviewed
literature. This information will do well to inform the disease cost models that have been created
for this thesis.
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Another industry report seems to confirm these findings. The October 2017 “Orphan
Drugs in the United States” report published by the Quintiles Institute in New Jersey shows that
median annual cost per patient per year to also be around $80,000.10 This report used the FDA
orphan drug database to generate a list of all orphan drugs currently being offered in the US,
they then used the IMS Health database (a database that provides physician prescribing data)
to assign prescription rates and prices to each drug. This report did not take into account
anything other than direct medical costs. While direct spending can often make up the majority
of an individual's costs for treatment, it rarely makes up the total spending. Rare disease
patients can end up spending a significant amount on specialist visits, tests, transportation, and
home care. Other than individual cost, the report by the Quintiles Institute mainly focuses on the
growth of spending on rare diseases and orphan drugs in the US. The report goes on to say that
of the $450 billion of drug sales in the US, $36 Billion is spent on rare diseases, which is about
8%.10 These types of findings in the report suggest that the reports are mainly tailored to
investors in the pharmaceutical industry.
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A separate industry impact report took a survey of over 100 rare disease patients and
their caregivers in the US.11 The report was sponsored by the rare disease therapy company
known as Shire Human Genetic Therapies and was conducted through the RARE Project (a NJ
based genetic disease advocacy group). This report mainly goes into the social, emotional, and
health care impacts of rare disease. The report goes on to say that individuals with rare
diseases experience a quality of life that is 60% worse than the average healthy person. They
found that 53% of individuals in the US with rare diseases had to borrow money to pay their bills
and that 55% of that same population incurred direct medical costs that were not covered by
their insurance. Offering a more social perspective, the Impact Report continues to say that a
large amount of costs due to rare disease are indirect and that 61% of patients are diagnosed
with untreatable depression linked to their condition.
The information from these sources seems to show that most individuals are willing to
pay, or at least have to pay, very high prices for healthcare related to their disease. This
information also suggests that genetic diseases have high costs both socially and economically.
This means that as a society, or as individuals, we should be willing to pay equally high prices to
eliminate genetic disease altogether.
In mentioning limitations, most articles mention that direct medical costs do not represent
the total of costs associated with a genetic disease. Direct medical costs, indirect medical costs,
and social costs (if quantifiable) would make up the sum total of cost for a genetic disease
patient and are respectfully harder to calculate. Three of the eight articles mention that indirect
medical costs most likely exceed direct medical costs per patient. This means that in most
cases direct medical costs may represent less than half of total costs incurred by genetic
diseases. Most articles do not directly mention this as a limitation. These same papers also look
at genetic disease as a whole. While most articles use figures for the “average genetic disease”,
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no genetic disease case is average. When looking into data on individual diseases it can be
seen that annual costs can vary between diseases by a factor of 100x.12 Genetic diseases are
highly varied and should be looked at with fine granularity in order to understand the full picture.
Another limitation of the studies comes from those that conducted surveys. Of the three articles
that included survey data, none of them actually conducted the survey themselves and were
citing data that was collected by other institutions; one of them directly mentioned this as a
limitation.
Finally, most articles aimed to analyze both the social and the economic costs
associated with genetic diseases. It should be made very clear that all costs associated with
genetic disease are worth considering and that the social and moral burden of genetic diseases
and their possible cures hold considerable value. However, this review aims only to determine
the extent of research into direct medical costs to genetic disease patients. Social, moral, and
ethical implications of these topics are out of scope for this analysis.

Literature Review Discussion
Precisely editing the DNA of an organism, human or otherwise, has been considered
both extremely difficult, inaccurate, and exceptionally costly up until the last decade. In 2013,
scientists from MIT and UC Berkeley published research showing that they had discovered a set
of enzymes called “C.R.I.S.P.R”. This set of enzymes, when utilized correctly, gave researchers
the ability to edit the DNA of any organism with extreme accuracy.13 Since then, there has been
substantial speculation in the scientific community about the uses for this technology. The idea
of cheap and accurate gene editing is certainly enough to lead anyone to think about the many
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implications of such technology, and with CRISPR these implications are now more possible
than ever.
Now that gene therapies are becoming safer, cheaper, and more precise, the effects of
this technology on our lives must be considered. Individuals with genetic diseases are an
obvious first target for genetic modification. A given genetic disease can cost an individual
considerable funds to treat, cause substantial suffering, and could feasibly be fixed using gene
editing technology. These individuals also represent a target for the biotech companies that
manufacture relief therapies that are non-genetic in nature. There are many individuals in the
US suffering from genetic diseases. The National Organization for Rare Disorders estimates
that approximately 25 million Americans or about 8% suffer from some type of rare disease.7
Looking at the literature as a whole, there seems to be agreement that the median
annual direct medical cost per patient across all genetic diseases is around $80,000 per year.
This figure includes the many extremely rare diseases with US patient counts below 1,000
persons.10 It is commonly accepted in the world of genetic diseases that the rarer a disease is
the more costly it is to treat. This follows with the basic supply and demand principle of
economics. The median annual direct medical costs per patient for some of the more common
genetic diseases is closer to $30,000 per year.8 Even when looking at only the most common
and therefore least costly genetic diseases one finds that annual direct medical costs are in the
tens of thousands of dollars.
Several articles analyze orphan drugs and rare disease as areas of financial growth and
investment. The orphan drug act offers companies the potential to form monopolies in treating
particular genetic diseases.10 Rare diseases and their treatments represent a $36 billion
industry. It makes sense that financially minded institutions would give attention to how this
market has grown and how this market is predicted to grow in the future. It could be said that
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this activity shows a large desire to profit from the genetic disease market and a possible lack of
incentivization to decrease prices of treatments for genetic diseases. This could mean that
theoretical cures to genetic disease may face pushback from large investment institutions, the
pharmaceutical industry, and other large healthcare stakeholders.
We must move forward carefully and respectfully as we advance this technology. The
information from these sources seems to show that most individuals are willing to pay, or at
least have to pay, very high prices ($80k avg) for healthcare related directly to genetic disease.
This information also suggests that genetic disease has high costs socially as well as
economically. As a society or as individuals we should be willing to pay equally high prices to
eliminate genetic disease altogether.
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Methods
The analysis of net present costs of various monogenic diseases to determine the direct
social benefits - the inverse of total cost of treatment when discounted down to a single value at
year zero of life - of gene therapy was performed from the societal perspective as well as the
perspective of an individual who wishes to remove a genetic disease from a human who has yet
to be born or has very recently been born and has a known risk or a family history of genetic
disease. The beginning of viable life has been chosen as the point of analysis for two reasons.
The first is because genome editing is much easier and effective when working with earlier
embryos and the concept of editing embryos has already been proven.1 The second reason is
that when the total lifetime costs are calculated with net present value analysis, using the
beginning of life as one’s starting point results in the lowest and most conservative lifetime cost
estimates because all of your potential costs are as far away as they could possibly be in one’s
lifetime. Costs will be calculated from the social perspective (i.e the sum total direct costs to
both the insurance provider and the individual).14 Indirect medical costs (i.e reduced productivity,
work loss, lost taxable income, travel to specialist, expenses, etc) 14
 will not be within the scope
of this study. The social, emotional, and ethical benefits of a life free from genetic diseases are
abundant but undefined and are out of the scope of this thesis. The economic benefits also
remain largely unexplored and will be the sole focus of this thesis. It would be an obvious desire
of any caretaker to remove a genetic disease from their future offspring. Given that the answer
to the question “Should I pay for gene therapy?” is most likely an emphatic “yes” from most
caretakers faced with the possibility of genetic disease in their offspring, the main goal of this
thesis is to help aid individuals in determining if gene therapy is economically justified. In order
to accomplish this, the economic benefit of removing the direct medical costs associated with a
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lifetime of a given genetic disease at different discount rates will be used as a stand-in to
determine direct social cost. For use within this thesis, this direct social cost stand-in will be
acceptable, however it should be noted that it is not without its complications, which are detailed
throughout this thesis.
The direct medical costs of each disease are the primary data input for the analysis of
lifetime costs. Direct medical costs are those that apply directly to medications, medical care,
hospital visits, and physician fees. These costs are easily documented and are made up of
elements that are commonly covered by both private and public healthcare providers. Direct
medical costs were chosen as the main base of analysis in the interest of creating concrete and
conservative estimates that will have relevance to policy making in the domains of health
insurance and government. It should be mentioned that total medical costs for rare disease,
which are made up of the sum of direct and indirect medical costs, have been shown to be
mainly comprised of indirect medical costs.15 Indirect medical costs (costs comprising of work
loss, lost taxable income, travel to specialists, expenses, etc) are harder to calculate than direct
costs and also vary widely among individuals. Given that indirect medical costs can make up the
majority of costs to an individual with a rare disease it should be considered that, while the
estimates in this thesis are purposefully conservative, an estimate for total costs associated with
a disease could be over double the amount of direct medical costs.
The main goal of these methods will be to produce a lifetime direct medical cost
distribution for a given genetic disease. Then to take these cost distributions and equate them to
a single lump cost at the beginning of life using net present value calculations. That lump sum
cost will be used as a conservative limit for estimating a direct social benefit for prenatal genetic
therapy. Diseases to be analyzed will be the most common monogenic (single gene) diseases.
Monogenic diseases represent a feasible target for upcoming human gene therapies because
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erroneous genetic material is limited to a single location in the genome are often as simple as a
single incorrect or missing letter in the DNA sequence. The data is collected from research
papers with the intent of investigating the direct medical costs of a given monogenic disease.
Direct medical cost figures are collected before the costs are split between the health insurance
provider and the patient. The existence and prevalence of direct medical cost data will help to
compensate for the intricate nature of the US health insurance system. The cost data utilized
will come from the most recent research papers published within the last 10 years in the US that
have statistically significant sample sizes. Other inclusion criteria is outlined are the Data section
of this thesis.
In order to accurately quantify a lifetime of payments into a single lump sum of money, a
“net present value” of the payments must be calculated. A Net Present Value (NPV) is a term
used in economics to describe the worth of a present sum of money as compared to a future
sum or sums of money with respect to a discount rate. The concept of NPV is based on the
principle that money is worth more right now and worth less the further into the future you go.
Discount rates are expressed as a percent and roughly correlates to how much return on
investment an individual or institution needs in order to find an investment acceptable. Privately
acting individuals might operate with a discount rate between 3% and 7%, larger corporations
and institutions like health insurance and pharmaceutical companies might operate with
discount rates between 10% and 30%.16
Monte Carlo analysis techniques will be used to account for the high variability in yearly
costs of genetic diseases, as well as variability in diagnosis age and expected lifetimes. Monte
Carlo analysis works by simulating hundreds, or in this case thousands, of different possible
scenarios to determine a probabilistic breakdown of possible outcomes. This will work well to
give most likely cost figures and distributions for each disease. All of the considered diseases
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have different stages, average onset ages, mortality ages, and severities, each with different
costs associated with them. These cost factors will all be considered in the model. For example,
a lifetime direct medical cost breakdown for Huntington's disease may look like Figure 2 below.
It can be seen that the disease starts incurring costs later in life with the price increasing in three
stages over time. Once a distribution of the lifetime annual direct medical costs for each disease
is generated the costs will then be calculated into a single lump sum at one year before birth.
Figure 2

Each lifetime disease cost estimate is produced by simulating thousands of theoretical
individuals, each with different variables associated with their disease and costs and defined by
statistically significant input data. The net present value of each individual's lifetime direct
medical spending is then calculated and added to the pool of all theoretical individuals with the
given disease to determine the final cost distribution. Once the cost distributions are generated
in the Monte Carlo model for each disease they can be adjusted for sensitivity analysis. Such
analysis would include different discount rates for the NPV calculations, the possibility of an
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individual having a child with the same disease, and different onset ages for each stage. Using
the example of Huntington’s disease, the cost data and onset ages of the different stages and
their variabilities would be added to the model to reflect the stepped increase of costs over time
in an individual's life.
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Data
In order to accurately and robustly answer the question posed by this thesis a
representative number of genetic diseases must be considered. Several methods of disease
selection have been considered for this process. The method that is currently the most
reasonable is to include a selection of the most common monogenic disorders. Monogenic
diseases make up the some of the most common genetic disorders and have the highest
likelihood of benefitting from CRISPR based genetic therapy. Monogenic diseases are a subset
of genetic diseases where there is only a single gene mutated or missing. Collecting data on the
annual treatment costs of these diseases is key. Most genetic diseases have advocacy groups
associated with them. These advocacy groups tend to collect data regarding the costs
associated with their genetic disease. Input data comes primarily from these groups and various
other institutions carrying out surveys for the collection of cost data.
The criteria for data inclusion began by searching for monogenic (single gene) diseases
as they are most likely to be treated by upcoming gene editing technology. From that list only
the monogenic diseases which were most prevalent in the US population according to the US
Center for Disease Control’s resources were selected. The search for cost data began with the
most prevalent and moved to the least prevalent as time allowed. In total, nine diseases were
included in this thesis. For each disease only research that included data specifically regarding
direct medical costs or direct medical resource utilization was included. Data from Medicare and
Medicaid was prioritized where available in order to produce more conservative cost estimates.
Data from surveys within the last 10 years and data with the largest sample sizes were also
prioritized.
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Data on nine different diseases has been collected. A summary of that data can be seen
in the tables 2 and 3 above. Additional cost data which relates to the different stages of each
disease are not included in the summary table but are included in the model. These additional
data are mentioned in the Disease section. In the data most of the diseases show median costs
which are lower than the average costs and some standard deviations which were higher than
the mean. This reinforces that most individual diseases also closely follow lognormal
distributions of cost. Medicare and Medicaid costs are both utilized in the models. They are both
government run health insurance programs that help cover elderly and low income individuals
respectively. Prices for various healthcare products (i.e. prescription drugs, hospital stays,
surgeries, etc) are negotiated by the government with these two systems and tend to be lower
than prices set by private health insurance entities. This is a simplification of the Medicare and
Medicaid systems, however, the result is that using prices set for the Medicare and Medicaid
systems allows for accurately conservative cost estimates in general.
Table 3 shows that Polycystic Kidney Disease has a different clinical prevalence than
that which has been reflected by surveys estimating the current number of individuals suffering
from the disease in the US population. This is because Polycystic Kidney Disease usually only
presents in late middle age and some individuals can be asymptomatic for the entirety of their
lives. It is not uncommon for an individual with Polycystic Kidney Disease to die (either of kidney
related causes or other causes) and to have their disease revealed and diagnosed via autopsy
or postmortem blood work.17 It can also be seen in table 3 that recessive diseases are shown to
have 100% of their cases occur with little or no family history. This is a simplification. It is
certainly possible for individuals to be born with these recessive genetic diseases and also have
family history, although these cases a much rarer. This simplification has been made in order to
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streamline some of the analysis performed in this thesis, particularly the White Pill thought
experiment which can be found in the Results section.
All genetic diseases are worthy of consideration, the diseases in this thesis have been
chosen for their readily available and recently published data along with their theoretical ease of
treatment with gene editing technologies. There are several monogenic diseases, including
Familial Hypercholesterolemia, Hereditary Spherocytosis, β -Thalassemia, and
Neurofibromatosis, that are more common in the US and World populations than several of the
diseases chosen for analysis in this thesis. These diseases were not included due to their highly
complex nature and high variance between individuals which makes basic economic tracking
difficult. The omission of these diseases is not a deliberate rejection but a recognition that there
is still much to be understood about the economics of genetic diseases.
β -Thalassemia is a prime example of one of these diseases. It happens to be one of
the most prevalent genetic diseases in the world and is as common as 1 in 10,000 in certain
countries.18 However, β -Thalassemia mostly affects demographics that are not extremely
common in the United States (namely Italian, Greek, Middle Eastern, and South Asian). β
-Thalassemia also presents a wide range of symptoms from dizziness to enlarged spleen.18 This
combination of factors in a disease makes it hard to accurately track costs in US dollars even
though it is a relatively common genetic disease and is prevalent worldwide.
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Diseases
The following section provides overviews of each disease and relevant information
regarding medical resource utilization for the generation of lifetime cost models. Information
regarding disease symptoms comes primarily from the CDC’s index of diseases and conditions
19 

unless otherwise cited.

Cystic Fibrosis (CF)
Cystic Fibrosis is a disease where the secretions of the body are unusually thick. The
disease is most prevalent in the lungs as they can build up with mucus. The liver, pancreas,
kidneys and intestine can also be affected. Cystic Fibrosis is usually diagnosed within the first
year of life and is associated with a diminished life expectancy of approximately 47 years.20
Antibiotics and other medications are often prescribed to ward off lung infections and increase
quality of life. In some cases as lung condition worsens mechanical breathing and even lung
transplantation may be necessary.

Sickle Cell Disease (SCD)
Sickle Cell Disease is a blood disorder caused by an abnormality in the gene for
hemoglobin and is also commonly known as Sickle Cell Anemia. The most prominent feature of
this disease is that the defective hemoglobin causes some blood cells to deform into crescent or
sickle shapes. These abnormally shaped blood cells can get caught in capillaries and cause
various kinds of damage throughout the body. Symptoms include pain crisis, acute chest
syndrome, aplastic crisis, fatigue, and many others. Diagnosis is often within the first year of life
and can be done with a simple blood test. SCD is associated with a lifespan shortened to
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around 45 years.44 Treatment for SCD includes daily administration of penicillin for individuals
under six years old, pain medication, blood transfusions, prescription Hydroxyurea, and others.
The data collected utilizes Medicaid dollars.43

Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy is a severe form of muscular dystrophy which is
hallmarked by muscle weakness in the legs which eventually develops into widespread muscle
weakness. DMD is an X linked disease so it disproportionately affects males. Treatments
include prescription of corticosteroids, use of orthopedic appliances such as leg braces and
wheelchairs, and a volume ventilator/respirator for sleep hours which may eventually be needed
for all hours. Other treatments may also be used. Symptoms for DMD usually begin around age
five.21 No significant data could be found resolving the distribution of onset age further, so an
average onset age of five years with a standard deviation of one year was used in the model to
add as much accuracy as possible. The available cost data is calculated in “international
dollars” which is based on the buying power of the US dollar in the US, so it is functionally
equivalent to a US dollar. The main study from which the cost data was taken did not explicitly
state whether or not it used Medicare or Medicaid data,22 in the case that it did not, this may
explain why the estimates seem higher than what might be intuitively concluded. In a separate
cost analysis of DMD it is suggested the costs usually double around age 14,23 however the cost
figures of that study did not meet inclusion criteria for this thesis. The second cost analysis
study suggests that total loss of mobility is correlated with an increase in medical costs and is
known to happen about halfway through the course of the disease. This is still accounted for in
the model by having the costs set to 65% of the known lifetime mean for the first half of life and
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135% of the known lifetime mean for the second half of life. Life expectancy with DMD is
approximated at 35 years.23

Hemophilia A (HA)
Hemophilia A is a disorder in the blood's clotting mechanisms which impairs the body’s
ability to form clots which can lead to excessive bleeding along with joint swelling and other
symptoms. Diagnosis is typical within the first year of life.24 Treatment can include the use of
prescribed clotting factors based on severity, also prescribed pain medications, steroids, and
physical therapy can be used to decrease pain. No research on life expectancy that meets
inclusion requirements for this thesis could be found. Most life expectancy research is either
from over two decades ago or includes a sample population which is not statistically significant.
The World Hemophilia Organization does include in their annual report that most hemophilia
patients live to be over 45 years old and that “Without adequate treatment, many people with
hemophilia die before they reach adulthood”.25 However, with proper treatment “life expectancy
for people with hemophilia is about 10 years less than that of males without hemophilia”.26 With
this, it will be assumed that hemophilia morality is about 10 years earlier than that of the
average US life expectancy which is 68 compared to the US average of 78.26 The data used in
the model utilizes Medicare and Medicaid data. 25


Huntington’s Disease (HD)
Huntington’s Disease or HD is a genetic disease associated with the slow death of brain
cells beginning in middle age. Early stages of the disease are associated with affected mood,
mental ability, and coordination. Later stages are associated with dementia, and total loss of
motor control. Symptoms of early stages can be treated with various pharmaceuticals, however
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as the disease progresses and psychomotor function declines individuals with HD will require
full time care. The Huntington’s model was made using stage based costs from a 2013 study of
direct medical costs.27 The distributions for age of onset were taken from a separate piece of
research which specifically studied onset ages and length of disease stages.28 Based on this
data, the model assumes an average age of onset of 40 (SD 12) and an average duration until
end of life of 20 years (SD 2). Extreme cases of Huntington's onset in very early or very late life
(before the age of 30 or after the age of 60) have been known to correlate with shortened
subsequent stage durations and lifespans, however, these represent fringe cases and will not
be incorporated into the model. 28
 29 The progression of the disease has three stages. Early
stage, middle stage and late stage are associated with annual costs of $3,257 (SD $5,670),
$12,330 (SD $16,986), and $34,495 ($27,111) respectively.27 It is assumed that each stage
lasts about one third of the total time between onset and end of life which is based on a
probabilistically generated onset age. HD represents an interesting genetic disease for this
economic analysis because symptoms and treatment do not start until around 40 years of age.29
This puts all the costs associated with HD at the end of life and therefore results in a low net
present value when compared to diseases with similar treatments. This low relative net present
value makes HD an exemplary case for the lower bound of the lifetime cost of any genetic
disease.

Polycystic Kidney Disease (PKD)
Also known as Autosomal Dominant Polycystic Kidney Disease or ADPKD, it is one of
the most common genetic diseases in the US. PKD is hallmarked by the slow accumulation of
numerous fluid filled cysts that grow on the kidneys and cause degenerative kidney failure. PKD
takes several decades to develop symptoms that can be noticed clinically, this is why many
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patients are not diagnosed until symptoms onset in middle age. Seven separate stages are
identified with the progression of PKD. These stages and their rounded associated mean annual
costs are stage 1: $10,500 (SD $25,000), stage 2: $8,600 (SD $28,000), stage 3: $10,700 (SD
$31,000), stage 4: $15,600 (SD $30,000), stage 5 $45,500 (SD $65,300), dialysis: $57,900 (SD
$79,000), and post-transplantation: $32,200 (SD 52,000).29 Stages 1-5 are associated with
measured decline in kidney function until failure. After the five stages an individual must
undergo dialysis until a transplant can be found. It is assumed that each stage lasts 2 years,
dialysis lasts 3.5 years 30
 , and the post transplantation stage lasts until end of life. An estimate
based on data published in the New England Journal of Medicine has PKD affecting
approximately 1 in 2500 Americans.31 This makes PKD the most common chronic genetic
disease in the US. Approximately 10% of all renal replacement therapy in the US and a
significant number of US kidney transplants are utilized by PKD patients.32 Steadily removing
the burden of PKD from the US transplant and renal replacement systems could mean a lot for
those who remain in those systems.

Gaucher Disease (GD)
Gaucher Disease is what's known as a lysosomal storage disorder. The body cells in
individuals with this disease lack an enzyme that allows for the removal of wastes known as
sphingolipids. These wastes then build up in the liver, kidneys, lungs, brain, and other organs.
The buildup of wastes is slow, so it may take years for an individual to begin showing symptoms
and be properly diagnosed.33 The drugs used to treat GD, known as enzyme replacement
therapies or ERT, make for an interesting case because they alleviate the symptoms of the
disease almost totally. An individual who has been receiving ERT for GD would, almost
miraculously, show almost no symptoms of the disease. This means that an individual with GD
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has very few direct medical costs associated with their disease other than those associated with
their ERT.34 The average annual cost data for GD was calculated by averaging the annual cost
for the drugs used to treat the disease, and the standard deviation required for the model was
taken from the standard deviation of the different drug prices.

Hereditary Angioedema, Type 1 (HAE)
Hereditary Angioedema type 1 is the most common form of HAE and is primarily caused
by a deficiency in blood proteins that suppress the body's inflammatory system. Overstimulation
of the inflammatory system can cause severe swelling in the arms, legs, face, and intestinal
tract. In some cases, swelling can occur in the airways of patients which, without immediate
medical attention, can lead to asphyxiation. Various prescription drugs can be taken to decrease
the frequency and severity of swelling episodes. Some patients may be prescribed an enzyme
replacement therapy to help restore their deficient blood proteins. No standard deviation data
was available with the HAE annual cost data used in this paper. Any HAE research that did
include standard deviations with the annual cost data did not meet the inclusion criteria for this
paper. Knowing that HAE is a dynamic disease with many varied symptoms, a standard
deviation needed to be approximated for the annual per patient cost data in the model. This
standard deviation was made by averaging the ratios of the standard deviations of each disease
to their direct medical costs. Most of the monogenic diseases represented in this thesis have
direct medical costs with standard deviations that come close to or exceed the mean.
The standard deviation produced by this method was 91%. While this method may not be
entirely accurate It has provided a standard deviation which approximates a common
monogenic disease.
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Pompe Disease (PD)
Pompe Disease (PD) is also known as glycogen storage disease type II, Pompe Disease
is another lysosomal storage disease similar to Gaucher’s Disease which primarily affects
juveniles. PD is associated with the buildup of complex sugars in certain tissues and organs,
especially the muscles.35 Poor muscle tone, enlarged liver, heart defects, and developmental
disorders are hallmarks of this disease. PD is also associated with an extremely attenuated
lifespan.36 PD is another disease which can be treated with enzyme replacement therapy. Cost
is variable by an individual’s weight. The annual cost for an infant/juvenile being approximately
$100,000. 37
 Approximate cost for adults is around $300,000 annually given their increase in
size and switch to a slightly different adult version of the drug.38 These drugs have had fairly
consistent prices since their inception, because of this a fairly low standard deviation relative to
the mean (10%) was used in the model 8 and is based on the drug’s fluctuation in prices since
approved. The lifesaving enzyme replacement therapy which makes up the primary component
of the cost of Pompe Disease was recently approved by the FDA in 2006 and had clinical trials
of the therapy in the years leading up to it.38 Due to the therapy’s recent approval, only now are
some of the individuals who participated in early clinical trials beginning to live into their 20s.39
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Results
Cystic Fibrosis (CF)
Figure 3

Figure 3 shows the estimated lifetime direct medical costs for Cystic Fibrosis as probabilistic
distributions of lifetime direct medical cost at seven different discount rates. The distributions for
Cystic Fibrosis are mostly normal bell shaped curves.
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Sickle Cell Disease (SCD)
Figure 4

Figure 4 shows the estimated lifetime direct medical costs for Sickle Cell Disease as
probabilistic distributions of lifetime direct medical cost at seven different discount rates. The
distributions for SCD follow normal bell shaped curves.
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Duchenne Muscular Dystrophy (DMD)
Figure 5

Figure 5 shows the estimated lifetime direct medical costs for Duchenne Muscular Dystrophy as
probabilistic distributions of lifetime direct medical cost at seven different discount rates. The
distributions for DMD follow normal bell shaped curves.
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Hemophilia A (HA)

Figure 6

Figure 6 shows the estimated lifetime direct medical costs for Hemophilia A as probabilistic
distributions of lifetime direct medical cost at seven different discount rates. The distributions for
HA follow normal bell shaped curves.
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Huntington’s Disease (HD)
Figure 7

Huntington’s disease has the lowest calculated NPV of any monogenic disease covered in this
thesis. Due to the low relative NPV and the onset of the disease later in life, the higher discount
rates produce distributions that are highly clustered close to $0 in Figure 6. To increase overall
comprehension of Figure 6, all discount rate distributions of 10% and above have been removed
from the chart. The mean and SD of those higher discount rates for Huntington’s can be found
in Table 4.
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Polycystic Kidney Disease (PKD)
Figure 8

There are relatively few people with severe forms of Polycystic Kidney Disease, however the
direct medical costs increase dramatically with severity. This leads to distributions with left
skewed peaks and long rightward tails as can be seen in Figure 8. To increase overall
comprehension of Figure 8, all discount rate distributions of 10% and above have been removed
from the chart. The mean and SD of those higher discount rates for PKD can be found in the
Ranking Direct Social Cost table below.
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Gaucher Disease (GD)
Figure 9

Small spikes in the tails of the distributions for Gaucher Disease in Figure 9. These small spikes
most likely represent cases which are diagnosed and begin treatment within the first year of life.
This causes a high cost in the NPV calculation because costs in year zero are not subject to
discounting in the direct medical cost distribution model.
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Hereditary Angioedema Type 1 (HAE)
Figure 10

Figure 10 shows the estimated lifetime direct medical costs for Hereditary Angioedema Type 1
as probabilistic distributions of lifetime direct medical cost at seven different discount rates. The
distributions for HAE follow normal bell shaped curves.
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Pompe Disease (PD)
Figure 11

Figure 11 shows shows the estimated lifetime direct medical costs for Pompe Disease at seven
different discount rates..There is some irregularity in the distributions which might be explained
by a diagnosis of the disease close to birth and high direct medical costs thereafter.
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Detailed Distributions of all Included Diseases:
Figure 12

It can be seen in Figure 12 that the nine chosen diseases represent a wide range of lifetime cost
distributions. The higher a spike is for one of these diseases the more predictable the lifetime
costs are according to this model. The further to the right a disease’s distribution is the higher
the average lifetime cost. While having all the different cost distributions placed on a single
graph may be somewhat disorienting, it is important to visualize the stark differences between
them. Some diseases, like PKD and Huntington’s Disease, occur later in life and have lower and
more predictable costs which lead to tighter distributions and a lower average net present value.
Other diseases, like Pompe Disease and Gaucher Disease, have very unpredictable associated
lifespans along with higher costs incurred earlier in life which lead to very spread out
distributions with very high net present costs. Hemophilia A, which can be seen at the far right of

48

Figure 12, has both the highest costs and one of the largest associated variability. This is most
likely because Hemophilia A can range greatly in severity between individuals. Individuals with
Hemophilia A also tend to live life spans of about average length and have high annual costs
throughout their lives. Another interesting note is that the Hemophilia model used Medicare and
Medicaid data as its inputs. These sources are known to produce more conservative cost
estimates. Despite this, Hemophilia still has the highest lifetime cost of any disease in this
thesis.
All inputs into this net present value model were chosen in order to generate a
conservative cost estimate per disease which would in turn give a conservative maximum direct
social benefit per removal of disease associated medical costs. Direct medical cost estimates
from Medicare and Medicaid were used whenever available, the usefulness of this is explained
in the Data section of this thesis. The cost analysis also begins at year zero of an individual's
life. This is for two reasons; the first is to provide a cost estimate over an entire lifetime of an
individual, the second reason is to provide a conservative net present value analysis. The costs
of each disease in this thesis continue all the way until the end of life, therefore, performing the
net present value analysis at year zero results in the lowest and most conservative total cost
estimate.
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Ranked Direct Social Cost Table

Table 4:

The numbers in Table 4 represent a conservative estimate for the maximum direct social
benefit for a theoretical gene therapy which would remove the symptoms of, and therefore the
direct medical costs of, a given genetic disease over a lifetime. The diseases are arranged in
the table according to the value of each at the 5% discount rate with the highest value at the top
of Table 4. An economically rational entity operating from the social perspective should be
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willing to pay no more than the costs shown above to offset a lifetime's worth of direct medical
costs associated with a given genetic disease.

“White Pill” - Gene Therapy Analysis
The following analysis takes the results of this thesis a step further and applies the costs
to the US population in general. It happens very often in the healthcare system that individuals
are faced with the decision to spend resources in order to avoid risk. This analysis attempts to
establish a baseline willingness to pay for the removal of the cost risk associated with being
born with, and incurring costs related to, a genetic disease. It has been demonstrated in this
thesis that the costs of a lifetime with a common monogenic disease can be very high, however,
the chance that an individual being born with one of these diseases given no known family
history is very low. This analysis will hopefully add perspective to both the huge costs
associated with common monogenic diseases and the low probability of being born with one of
these diseases.
This analysis assumes the following theoretical situation adapted from Ronald Howard’s
famous Black Pill / White Pill thought experiment 40
 : an individual acting for the maximization of
social benefit is offered the chance to distribute a theoretical therapy to prenatal patients that
will surely repair any genes associated with a given genetic disease and therefore remove all
direct medical costs associated with a lifetime of that disease. If a given patient does not receive
a pill then they are subject to the normal (very low) probabilities associated with living their
entire life with a monogenic disease. Therefore, how much should that individual be willing to
pay per pill?
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Table 5:

Table 5 shows an evaluation of the willingness to pay from the social perspective to
avoid the risk of a lifetime of costs associated with a genetic disease as outlined by the thought
experiment above. The figures in Table 5 were generated by multiplying the chance of an
individual within the US population being born with a given genetic disease and having no family
history of the given genetic disease, by an estimated US population of 330 million people, by the
average direct medical costs per disease per discount rate which can be found in table 4.
(P robability of birth with genetic disease) × (Average cost per disease) × (U S population) = (Risk avoidance payment)

To give an example using this data, if the individual in the thought experiment above
were operating with a discount rate of 5% then they should be willing to pay no more than about
$276 for a therapy to remove Cystic Fibrosis. Alternatively if this individual were acting to
remove Huntington’s Disease then the therapy should be worth no more than a few cents
regardless of discount rate. This Huntington's example produces such low values because
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being born with the disease without family history is so improbable and the costs associated
with the disease all occur in late middle age. Cystic Fibrosis, alternatively, is far more common
without family history and is generally more expensive over a lifetime.

“Magic Wand” Analysis
Table 6:

Table 6 represents a speculative analysis of what the cost savings might be from the
social perspective if each disease was completely removed from the US population using gene
therapy. The term “magic wand” is meant to hint at the improbability of this scenario. Table 6
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was generated by multiplying the prevalence in the US of each disease, by the US population,
by the net present value of the lifetime direct medical costs per disease as seen in Table 4. This
analysis is by no means perfectly accurate but I believe that it strongly hints at the large scale of
spending related to genetic disease in the US. Recognize that these figures are based only on
direct medical costs and do not take into account indirect medical costs associated with each
disease. Also, these figures do not account for the fact that the diseased populations within the
US are comprised of different age groups and are all born at different times. Another factor not
accounted for is that it would take some number of years to distribute gene therapies among the
population and that gene therapy may not be effective on all individuals. Even though this piece
of analysis has its flaws the implications are worth considering. Even the most heavily
discounted total figures imply a social cost savings of at least 40 billion dollars. As a rough
example, it is estimated by the Rare Disease Research Institute that CF costs about one billion
dollars per year in hospital visits alone.7 Multiplied by an average life expectancy of 48 years 17

and you get a very rough approximation of 48 billion dollars of cost for all the cystic fibrosis
patients in the US over their lifetimes. Total annual medical costs for SCD are also estimated to
cost 1.1 billion dollars per year.43 Multiplying this by the average SCD life expectancy of 43
years 44
 you get 47.3 billion dollars. To lend some perspective, the annual budget of NASA is
18.8 billion dollars.45
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Discussion
This thesis shows the extremely high prices that individuals should be willing to pay from
the social perspective for gene therapies which would remove all the direct medical costs
associated with a lifetime of monogenic disease. The idea of paying tens of thousands of dollars
for a single medical treatment may sound ridiculous at first, but when the alternative is paying
totals of hundreds of thousands of dollars then the idea becomes a little more reasonable.
Treating the symptoms of genetic diseases in the traditional ways can incur tremendous
costs over a lifetime. Removing the symptoms of these diseases from the lives of at risk
individuals has much more value than simply relieving the direct medical costs as was analyzed
in this thesis. It can be intuited that the treatment for the chronic conditions and symptoms
associated with genetic diseases would incur high direct medical costs. Therefore, it should
come as no surprise that an individual should be willing to pay an equally high price to remove
those costs and symptoms from a lifetime.
It is conceivable that insurance institutions with more long term agendas, such as
Medicare and Medicaid, would be well incentivized to pay for gene therapies which would
remove the direct medical costs of a disease, e.g. by functionally curing the disease. It can be
shown that other institutions and individuals would also be willing to pay for gene therapies with
curative and cost removing effects. An individual would have to be operating with an absurdly
high discount rate, over 30% in most cases, in order for the money they spent toward gene
therapy to not be worth it. It is clear that almost all sufferers of genetic disease and their
caretakers would be willing to pay for gene therapy with curative properties. Parents expecting
children would also be well incentivized to pay for these types of therapies too, especially if
there is associated family history of a given genetic disease.
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It is possible that the introduction of gene therapies which have costs that are within the
direct social cost estimates outlined by this thesis would face considerable pushback from
pharmaceutical and biotech companies, particularly those companies which produce enzyme
replacement therapies and drugs used to treat some of the diseases brought up in this paper. In
the case of enzyme replacement therapies for Pompe and Gaucher Disease, the average direct
social cost estimate represents about 10 years worth of treatment using currently manufactured
enzyme replacement therapy drugs.51 The possible loss to the drug companies represents a
lifetime's worth of payments from their patients. These pharmaceutical and biotech companies
stand to lose millions of dollars in potential revenue per patient if gene therapies are to be
implemented within their patient populations. Another threat to these companies is that their
patient populations in the US are very small, only a few thousand in some cases (NGF 2018).
This means that gene therapies have the potential to wipe out their patient populations entirely if
made affordable and accessible enough.
A lifetime with one of the monogenic diseases evaluated in this thesis costs a
considerable amount of money. Many of these diseases incur lifetime costs that exceed the
average US lifetime gained wealth of approximately 1 million dollars.52 It is more than likely that
individuals with these diseases will either need to have very good insurance or at least need to
borrow money in order to pay for their treatments.11 The therapeutic removal of these diseases
could result in a great deal of social benefit.
Given that a lifetime with one of these diseases can cost so much, most individuals
faced with the choice of either paying for corrective gene therapy or facing the direct medical
costs associated with the disease treatment would most likely be willing to choose the gene
therapy. It’s almost impossible to say what gene therapies in the future will cost, however given
the high relative cost of a lifetime with a genetic disease, there is a large opportunity for the
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companies providing these gene therapies to take advantage of vulnerable individuals by
charging unnecessarily high prices for life changing gene therapies. In the scenario that gene
therapies become relatively cheap to produce, it would be extremely unethical to upcharge
vulnerable individuals and create a situation where even a single individual was denied life
changing gene therapy due to inflated profit margins.
One policy implication that may result from prohibitively expensive gene therapy regards
health insurance companies. It is unclear how well incentivized they will be to cover gene
therapies if they cost several hundreds of thousands of dollars. Health insurance companies
would want to cover the cost of gene therapy so that they might avoid the future costs to treat
the symptoms of the genetic disease. However, if the upfront cost of gene therapy is
prohibitively expensive even for a health insurance company then that company might have a
valid reason to be concerned that the individual receiving the gene therapy would leave the
payer pool and take all the cost benefits of their gene therapy to another insurer. It may be
worth considering having individuals sign contracts with their health insurance companies so
that they might stay in the payer pool long enough to make the health insurance company’s
investment worthwhile.
To add analysis on something we stand to lose if the world moves forward with human
gene therapies: Sickle Cell Disease represents an interesting case for two reasons first that it is
unevenly distributed within the American population. Sickle cell affects approximately 1 in 3,000
Americans and about 1 in 700 African Americans according to the CDC’s webpage on Sickle
Cell Disease.19 Second is that it is autosomal recessive and requires an individual to have two
copies of the defective gene in order to cause any problems. If an individual only has one copy
of the gene and is a carrier, however, they will have high resistance to a deadly form of malaria
known as Plasmodium Falciparum 53
 . While purely speculative, genetic repair of the Sickle Cell
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gene could remove some potential benefits of Malaria resistance in current and future
generations. While the probability of contracting Malaria in the United States is functionally zero
and several effective antimalarial drugs are available to individuals wishing to travel to areas where
contracting the disease may be a problem. Curing Sickle Cell Disease could mean the removal of
Malaria resistance in many individuals. This would be considered a loss, even if a minor one.

Discussion up to this point has been concerned with individuals who have genetic
diseases, and with what the social benefit might be if their diseases were cured with gene
therapy. What is more difficult to consider is what these gene therapies might cost. The social
benefit associated with the removal of some of the more expensive monogenic diseases
covered in this thesis from a member of the general US population using a reasonable personal
discount rate of 3% or 5% is still several hundred dollars and can be seen in the “White Pill”
table. Current CRISPR gene editing kits cost about $1,000 3 . The Yale Genome Editing Center
already does custom genome editing work with mouse embryos. They currently charge around
$20,000 to produce a viable mouse embryo with a “knock in” gene of your choice.49 Pricing for
enzyme replacement therapies (ERTs) could be another benchmark for what gene therapies
might cost in the future. ERTs are produced using some of the same methods that a future gene
therapy might be and they are administered in a similar fashion. ERTs are produced in large
bioreactors and require a large amount of research to determine how the ERT might effectively
treat (but not cure) a genetic disease. VPRIV is an ERT used to treat Gaucher Disease and is
one of the more common ERTs, so it will be used as an example. VPRIV costs about $1,400 for
a vial with 400 units and requires 38 units per kilogram of bodyweight for a single course of
treatment.48 To treat a person with a bodyweight of 70kg it costs about $9,300. Currently prices
for new gene therapies are in the hundreds of thousands of dollars. 41
 42 46 It is hard to estimate
where the prices for these new technologies will be in a few years, but it is worth considering.
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Given adequate market pressures, a gene therapy could exist within the next decade or
so that could be within the direct social benefit thresholds for many of the diseases outlined
above. However, seeing that most diseases at most discount rates would need to be relatively
cheap for an individual to be willing to pay for them, it can be said that this theoretical therapy
may not be worth the investment for the average American yet.
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Conclusions
This thesis demonstrates the high direct social costs for treatments which would remove
a lifetime’s worth of costs associated with monogenic disease in individuals with know risk or
with family history. It is shown that the NPV of direct medical costs associated with several
common monogenic diseases can be very high. In the Direct Social Cost table it can be seen
that Huntington’s Disease represents the monogenic disease with the lowest average NPV of
lifetime direct medical costs at approximately $30,500 given a 5% discount rate as can be seen
in table 4. The monogenic disease with the highest average NPV in this thesis is Hemophilia A
with an average approximate NPV of $3,560,000 at the 5% discount rate. An approximate
estimate of willingness to pay for gene therapy within the general US population is also
calculated in this thesis. For example, based on a 5% discount rate the willingness to pay from
the social perspective for an individual in the US population for the removal of the suite of
monogenic diseases evaluated in this thesis would be approximately $490 per individual treated
given no family history of the disease as seen in Table 5. The disease in this thesis with the
highest estimated individual willingness to pay within the general US population using a 5%
discount rate is Cystic Fibrosis at approximately $275 per individual treated given no family
history of the disease. The disease with the lowest estimated willingness to pay within the US
population is Huntington’s disease with an approximate willingness to pay of less than $0.01 per
individual treated given no previous family history of the disease. Lastly, an evaluation of the
direct social cost savings in the US for the removal of the suite of monogenic diseases in this
thesis also shows that if all these diseases could “magically” be removed from the population
then the approximate overall savings would be 277 billion dollars given a discount rate of 5% as
seen in the Magic Wand Table.
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Ultimately this thesis comes to four main conclusions. First, that there are extremely high
lifetime direct medical costs associated with one of the monogenic diseases evaluated in this
thesis. The second main conclusion of this thesis is the existence of high theoretical direct
social benefit associated with the removal of the lifetime direct medical costs of these diseases.
Third, the relatively low willingness to pay for gene therapy for a member of the general US
population. The final main conclusion is that there is a potential social cost savings of billions of
dollars in the US if the diseases evaluated in this theses could be “magically” removed from the
population.
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